CurrentCardio
Get Weekly

CurrentCardio coverage · page 4 of 11

JACC: Cardiovascular Interventions

Briefs 121–160 of 433 CurrentCardio has covered from this journal, newest publication first

Latest from JACC: Cardiovascular Interventions

All coverage, newest first

  1. JACC Cardiovasc Interv

    Impact of Valve Frame Height on PCI Outcomes After TAVR

    Cohort studyValvular & structural

  2. JACC Cardiovasc Interv

    Transcatheter Tricuspid Valve Replacement and CLEFT After Tricuspid TEER

    Cohort studyValvular & structural

  3. JACC Cardiovasc Interv

    Tricuspid Valve Transcatheter Edge-to-Edge Repair in Patients With Cardiac Implantable Electronic Devices: Insights From EuroTR

    Cohort studyValvular & structural

  4. JACC Cardiovasc Interv

    Comparative Outcomes of Intracardiac vs Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion: Insights From EMERGE LAA Postapproval Study

    Cohort studyArrhythmias & EP

  5. JACC Cardiovasc Interv

    Hypoattenuated Leaflet Thickening and Reduced Leaflet Motion After Transcatheter Tricuspid Valve Replacement

    Cohort studyValvular & structural

  6. JACC Cardiovasc Interv

    New-Onset Conductance Disturbances After Transcatheter Tricuspid Valve Replacement: A Mechanistic Assessment

    Cohort studyValvular & structural

  7. JACC Cardiovasc Interv

    Outcomes of Stroke Prevention Strategies in Patients With Atrial Fibrillation and End-Stage Renal Disease

    Cohort studyArrhythmias & EP

  8. JACC Cardiovasc Interv

    Association Between Angiography-Derived Murray Law–Based Quantitative Flow Ratio and 1-Year Coronary Artery Bypass Graft Patency

    Cohort studyCoronary & ACS

  9. JACC Cardiovasc Interv

    CLASP IID Trial and Registry: 2-Year Outcomes of Transcatheter Repair for Degenerative Mitral Regurgitation

    Randomised controlled trialValvular & structural

  10. JACC Cardiovasc Interv

    Electrosurgical Leaflet Modification to Prevent Coronary Obstruction During Transcatheter Aortic Valve Replacement in Failing Native and Bioprosthetic Valves

    Cohort studyValvular & structural

  11. JACC Cardiovasc Interv

    Intravascular Imaging vs Angiography Guidance for PCI of Severely Calcified Lesions: The ECLIPSE Trial

    Secondary analysisCoronary & ACS

  12. JACC Cardiovasc Interv

    Dual vs Single Antiplatelet Therapy After Transcatheter Aortic Valve Replacement for Bioprosthetic Valve Failure

    Cohort studyValvular & structural

  13. JACC Cardiovasc Interv

    1-Year Outcomes of Transfemoral Transcatheter Mitral Valve Replacement With the Eos System: The MISCEND Study

    Cohort studyValvular & structural

  14. JACC Cardiovasc Interv

    Acceleration Time/Ejection Time Ratio Compared to Mean Gradient as a Predictor of Clinical Outcomes Post-TAVR

    Cohort studyValvular & structural

  15. JACC Cardiovasc Interv

    Drug-Coated Balloons in the European Registry of Chronic Total Occlusion: The ERCTO Registry

    Cohort studyCoronary & ACS

  16. JACC Cardiovasc Interv

    Percutaneous Coronary Intervention in Multivessel Disease and Infarct-Related Cardiogenic Shock: A DanGer Shock Substudy

    Secondary analysisAcute care & resuscitation

  17. JACC Cardiovasc Interv

    Trends and Late Outcomes in Elderly Patients Undergoing Mitral Valve Interventions in the United States

    Cohort studyValvular & structural

  18. JACC Cardiovasc Interv

    Validation of Intravascular Ultrasound–Defined Optimal Stent Expansion Criteria for Favorable 1-Year Clinical Outcomes

    Meta-analysisCoronary & ACS

  19. JACC Cardiovasc Interv

    3-Year Outcomes of Drug-Eluting Stent vs Drug-Coated Balloon for Femoropopliteal Artery Lesions: Propensity Score-Matched Real-World Study

    Cohort studyAortic & peripheral

  20. JACC Cardiovasc Interv

    5-Year Outcomes With a Novel Coronary Sirolimus-Eluting Bioresorbable Scaffold: The NeoVas Randomized Trial

    Randomised controlled trialCoronary & ACS

  21. JACC Cardiovasc Interv

    Distal Radial Access for Radial Artery Recanalization: Multicenter Outcomes and Stepwise Strategies to Maximize Patency

    Cohort studyAortic & peripheral

  22. JACC Cardiovasc Interv

    30-Day and 1-Year Outcomes of Navitor Transcatheter Aortic Valve in Low- or Intermediate-Risk Patients

    Cohort studyValvular & structural

  23. JACC Cardiovasc Interv

    Refining Bleeding Risk Stratification After TAVR: Added Value of CT-ADP Beyond High Bleeding Risk Criteria

    Cohort studyValvular & structural

  24. JACC Cardiovasc Interv

    Early U.S. Commercial Experience With a Novel Transcatheter Edge-to-Edge Repair System: Insights From Real-World Data

    Cohort studyValvular & structural

  25. JACC Cardiovasc Interv

    Mid-Term Outcomes of Balloon-Expandable Aortic Valve-in-Valve Replacement in the United States

    Cohort studyValvular & structural

  26. JACC Cardiovasc Interv

    Aspirin or P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention for Acute Coronary Syndromes

    Meta-analysisCoronary & ACS

  27. JACC Cardiovasc Interv

    Bicaval TricValve Implantation in Patients With Severe Tricuspid Regurgitation: 1-Year Outcomes From the TricBicaval Registry

    Cohort studyValvular & structural

  28. JACC Cardiovasc Interv

    Atrioventricular Conduction Disturbances in Patients Undergoing Transcatheter Tricuspid Valve Intervention: A Multidisciplinary Consensus

    Research articleValvular & structural

  29. JACC Cardiovasc Interv

    Outcomes of Entrapped Right Ventricular Pacing or Defibrillator Leads Following Transcatheter Tricuspid Valve Replacement

    Cohort studyValvular & structural

  30. JACC Cardiovasc Interv

    Redefining TAVR Valve Sizing: A Validated Multiplanar Approach for Both Bicuspid and Tricuspid Valves

    Cohort studyValvular & structural

  31. JACC Cardiovasc Interv

    Same-Day Permanent Pacemaker Implantation Following Transcatheter Aortic Valve Replacement

    Cohort studyValvular & structural

  32. JACC Cardiovasc Interv

    The Relevance of Right Ventricular Function and Dimension in Patients Undergoing Transcatheter Tricuspid Edge-to-Edge Repair

    Cohort studyValvular & structural

  33. JACC Cardiovasc Interv

    Long-Term Outcomes of BAV-0 Patients Compared With BAV-1 and TAV Patients After TAVR

    Cohort studyValvular & structural

  34. JACC Cardiovasc Interv

    1-Year Outcomes of Transcatheter Arterialization of Deep Veins: PROMISE II and Pooled PROMISE Studies

    Meta-analysisAortic & peripheral

  35. JACC Cardiovasc Interv

    Outcomes of Lesions With Discordance Between FFR and Nonhyperemic Pressure Ratios

    Meta-analysisCoronary & ACS

  36. JACC Cardiovasc Interv

    Randomized Comparison of Fractional Flow Reserve and Instantaneous Wave Free Ratio in Serial Disease

    Randomised controlled trialCoronary & ACS

  37. JACC Cardiovasc Interv

    Vessel Patency After Femoropopliteal Drug-Coated Balloon Therapy in Patients on Hemodialysis

    Cohort studyAortic & peripheral

  38. JACC Cardiovasc Interv

    Incidence, Predictors, and Management of Conduction Disturbances After Transcatheter Tricuspid Valve Replacement: The TRIPLACE Registry

    Cohort studyValvular & structural

  39. JACC Cardiovasc Interv

    CT and Fluoroscopic Analyses of Valve Expansion in Redo-TAVR: A First-in-Human Report

    Cohort studyValvular & structural

  40. JACC Cardiovasc Interv

    30-Day and 1-Year Outcomes From the Optimize PRO TAVR Evolut FX Addendum Study

    Cohort studyValvular & structural

All 433 Briefs in ExploreShowing Briefs 121–160 of 433, newest first